JO
BTTX

John Overdeck’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

John Overdeck’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,192
Closed -$13.5K – 3283
2022
Q4 		$13.5K Sell
12,192
-6,682
-35% -$9.86K ﹤0.01% 2712
2022
Q3 		$33K Sell
18,874
-54,926
-74% -$100K ﹤0.01% 2348
2022
Q2 		$115K Buy
73,800
+8,008
+12% +$13.4K ﹤0.01% 2253
2022
Q1 		$130K Sell
65,792
-58,957
-47% -$204K ﹤0.01% 2402
2021
Q4 		$580K Buy
+124,749
New +$1.02M ﹤0.01% 3106

Other funds holding BTTX

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

John Overdeck's BTTX Position: Q1 2023 in Review

John Overdeck sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q1 2023, closing a stake of 12,192 shares — an estimated $13.5K sold.

John Overdeck first reported a position in BTTX in Q4 2021 and held it in 5 quarters. The position peaked at $580K in Q4 2021. 15 funds tracked by Wall St. Rank hold BTTX as of Q1 2023.

  • John Overdeck reported no remaining Better Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • John Overdeck sold 12,192 Better Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $13.5K.
  • John Overdeck first reported a position in Better Therapeutics, Inc. Common Stock in Q4 2021 and held it in 5 quarters.
  • John Overdeck's Better Therapeutics, Inc. Common Stock position peaked at $580K in Q4 2021.
  • 15 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Two Sigma Investments's 13F filing for Q1 2023, filed 15 May 2023.